Table 3

Risk factors for infection in patients with SLE receiving IV-CYC

Univariate analysisMultivariate analysis
With infection (n=177)Without infection (n=845)P valueOR (95% CI)P value
Age, years36.00 (29.00–50.00)39.00 (30.00–50.00)0.161
Sex (female:male)162:15772:730.943
CYC course (months)7.00 (5.00–12.00)6.00 (2.00–9.00)0.0000.964 (0.876 to 1.060)0.446
CYC accumulation (g)6.40 (4.45–9.00)4.80 (1.80–8.00)0.0001.092 (0.964 to 1.236)0.166
LN110 (62.15)463 (54.79)0.0731.246 (0.826 to 1.878)0.294
NPSLE24 (13.56)119 (14.08)0.855
Leucopaenia28 (15.82)82 (9.70)0.0172.266 (1.322 to 3.887)0.003*
Neutropaenia7 (3.95)13 (1.54)0.0351.159 (0.258 to 5.199)0.847
Lymphocytopaenia14 (7.91)28 (3.31)0.0051.371 (0.565 to 3.327)0.485
ILD16 (9.04)64 (7.57)0.509
PAH15 (8.47)31 (3.67)0.0052.756 (1.249 to 6.080)0.012*
Diabetes mellitus10 (5.65)31 (3.67)0.2221.635 (0.633 to 4.2240.310
SLEDAI6.00 (2.00–10.00)6.00 (2.00–10.00)0.451
CYC protocols
 SILD13.04% (66/506)86.96% (440/506)0.0012.018 (1.315 to 3.097)0.001*
 HD22.27% (57/256)77.73% (199/256)
Glucocorticoid pulse therapy20 (11.30)89 (10.53)0.764
Glucocorticoid dose (mg)22.0 (10.0–40.0)20.0 (10.0–45.0)0.871
 Group 1 (without Pred)22 (12.43)128 (15.15)
 Group 2 (≤15 mg/day)57 (32.20)278 (32.90)1.802 (0.865 to 3.753)0.116
 Group 3 (>15 mg/day)98 (55.37)439 (51.95)2.220 (1.097 to 4.489)0.027*
  • Data were presented as median (IQR) or n count (percentage).

  • *P value <0.05. All p values less than 0.05 which is significant are in bold.

  • CYC, cyclophosphamide; HD, high dose; ILD, interstitial lung disease; IV-CYC, intravenous cyclophosphamide; LN, lupus nephritis; NPSLE, neuropsychiatric SLE; PAH, pulmonary arterial hypertension; Pred, prednisone; SILD, short interval lower dose; SLEDAI, Systemic Erythematosus Disease Activity Index.